Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of “Buy” from Brokerages

Keros Therapeutics, Inc. (NASDAQ:KROS) has been assigned an average rating of “Buy” from the twelve ratings firms that are presently covering the company, MarketBeat reports. Twelve analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $88.89.

Several analysts have issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Jefferies Financial Group started coverage on shares of Keros Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating for the company. Bank of America reduced their target price on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research report on Thursday, September 12th. Wedbush reaffirmed an “outperform” rating and set a $84.00 target price on shares of Keros Therapeutics in a research report on Thursday, November 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a research report on Thursday, November 7th.

Hedge Funds Weigh In On Keros Therapeutics

Several institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC grew its holdings in Keros Therapeutics by 6.8% in the third quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock worth $42,146,000 after purchasing an additional 46,041 shares during the last quarter. Barclays PLC grew its holdings in Keros Therapeutics by 140.1% in the third quarter. Barclays PLC now owns 60,014 shares of the company’s stock worth $3,484,000 after purchasing an additional 35,022 shares during the last quarter. Wellington Management Group LLP purchased a new position in Keros Therapeutics in the third quarter worth $868,000. Point72 DIFC Ltd grew its holdings in Keros Therapeutics by 9.8% in the third quarter. Point72 DIFC Ltd now owns 19,255 shares of the company’s stock worth $1,118,000 after purchasing an additional 1,715 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after purchasing an additional 577,220 shares during the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Price Performance

Shares of NASDAQ KROS opened at $58.55 on Friday. The company has a market cap of $2.37 billion, a P/E ratio of -11.24 and a beta of 1.23. Keros Therapeutics has a 1 year low of $27.31 and a 1 year high of $73.00. The firm has a 50-day simple moving average of $59.43 and a two-hundred day simple moving average of $52.23.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. Keros Therapeutics’s revenue was up 4750.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.33) earnings per share. As a group, equities research analysts expect that Keros Therapeutics will post -5.28 EPS for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.